Search

Your search keyword '"Gilardi L"' showing total 5 results
Start Over Author "Gilardi L" Topic neoadjuvant therapy
5 results on '"Gilardi L"'

1. Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy.

Author

Corso G, Grana CM, Gilardi L, Baio SM, De Lorenzo D, Maisonneuve P, Rotmensz N, Ballardini B, Lissidini G, Ratini S, Bassi FD, Veronesi P, and Galimberti V

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anthracyclines administration & dosage, Anthracyclines pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents, Hormonal pharmacology, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms surgery, Feasibility Studies, Female, Humans, Lymph Node Excision, Lymph Nodes diagnostic imaging, Lymph Nodes drug effects, Lymph Nodes pathology, Middle Aged, Radiopharmaceuticals, Retrospective Studies, Taxoids administration & dosage, Taxoids pharmacology, Technetium Tc 99m Aggregated Albumin, Young Adult, Antineoplastic Agents therapeutic use, Breast Neoplasms pathology, Lymphatic Metastasis diagnostic imaging, Lymphoscintigraphy, Neoadjuvant Therapy, Sentinel Lymph Node diagnostic imaging
Abstract

Aim: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments., Material of Study: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery., Results: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients., Conclusions: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types., Key Words: Breast Cancer, Neo-Adjuvant Treatment, Sentinel lymphnode biopsy, Lymphoscintigraphy.

Published
2017

3. Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?

Author

Gilardi L and Paganelli G

Subjects
Biological Transport, Breast Neoplasms diagnosis, Breast Neoplasms metabolism, Fluorodeoxyglucose F18 metabolism, Humans, Lymphatic Metastasis, Positron-Emission Tomography, Tomography, X-Ray Computed, Treatment Outcome, Breast Neoplasms pathology, Breast Neoplasms therapy, Neoadjuvant Therapy
Published
2010
Full Text
View/download PDF

4. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.

Author

Gilardi L, De Cicco C, Colleoni M, Cardillo A, Montagna E, Dellapasqua S, Galimberti V, Bagnardi V, and Paganelli G

Subjects
Breast Neoplasms therapy, Humans, Middle Aged, Prospective Studies, Breast Neoplasms diagnostic imaging, Breast Neoplasms surgery, Fluorodeoxyglucose F18, Neoadjuvant Therapy, Patient Selection, Positron-Emission Tomography, Sentinel Lymph Node Biopsy
Abstract

Purpose: The main objective of this study was to determine the role of [(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the selection of patients with breast cancer as candidates for sentinel node biopsy (SNB) after neoadjuvant therapy., Methods: Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4(a-c) cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan. In the case of axillary FDG PET uptake, patients underwent axillary lymph node dissection (ALND). If the second FDG PET scan was negative for axillary involvement, SNB was performed in order to evaluate axillary lymph node status. Only in the case of SN positivity did total ALND follow., Results: Specificity and positive predictive value of FDG PET for detection of axillary lymph node metastases after neoadjuvant therapy were as high as 83% (95% confidence interval: 51-97%) and 85% (95% confidence interval: 54-97%), respectively, whereas sensitivity, negative predictive value and diagnostic accuracy were inadequate for a correct staging (34, 32 and 48%, respectively)., Conclusion: The poor sensitivity of FDG PET in detecting axillary lymph node metastases makes SNB mandatory in cases of a negative scan. The relatively high positive predictive value seems to suggest a role of FDG PET in selecting patients who, after neoadjuvant therapy, are candidates for ALND, avoiding SNB. However, this issue requires confirmation in a larger series of patients.

Published
2010
Full Text
View/download PDF

5. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy

Author

Vincenzo Bagnardi, Giovanni Paganelli, Anna Cardillo, Laura Gilardi, Silvia Dellapasqua, Marco Colleoni, Emilia Montagna, Concetta De Cicco, Viviana Galimberti, Gilardi, L, De Cicco, C, Colleoni, M, Cardillo, A, Montagna, E, Dellapasqua, S, Galimberti, V, Bagnardi, V, and Paganelli, G

Subjects
medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, NO, Breast cancer, Fluorodeoxyglucose F18, Axillary metastases, Nuclear Medicine and Imaging, Biopsy, medicine, Humans, Radiology, Nuclear Medicine and imaging, Prospective Studies, Neoadjuvant therapy, MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Fluorodeoxyglucose, medicine.diagnostic_test, Sentinel Lymph Node Biopsy, business.industry, Patient Selection, General Medicine, Middle Aged, Sentinel node, Axillary metastase, medicine.disease, Clinical trial, Positron emission tomography, Positron-Emission Tomography, Positron emission tomography (PET), Radiology, Nuclear Medicine and Imaging, Radiology, business, Emission computed tomography, medicine.drug
Abstract

Purpose The main objective of this study was to determine the role of [ 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the selection of patients with breast cancer as candidates for sentinel node biopsy (SNB) after neoadjuvant therapy. Methods Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4 a-c cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan. In the case of axillary FDG PET uptake, patients underwent axillary lymph node dissection (ALND). If the second FDG PET scan was negative for axillary involvement, SNB was performed in order to evaluate axillary lymph node status. Only in the case of SN positivity did total ALND follow. Results Specificity and positive predictive value of FDG PET for detection of axillary lymph node metastases after neoadjuvant therapy were as high as 83% (95% confidence interval: 51-97%) and 85% (95% confidence interval: 54-97%), respectively, whereas sensitivity, negative predictive value and diagnostic accuracy were inadequate for a correct staging (34, 32 and 48%, respectively). Conclusion The poor sensitivity of FDG PET in detecting axillary lymph node metastases makes SNB mandatory in cases of a negative scan. The relatively high positive predictive value seems to suggest a role of FDG PET in selecting patients who, after neoadjuvant therapy, are candidates for ALND, avoiding SNB. However, this issue requires confirmation in a larger series of patients. © Springer-Verlag 2010.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results